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Objectives. This study was designed to test the hypothesis that 
conversion of atrial flutter in humans by ibutilide, a new class III 
antiarrhythmic agent, is characterized by an increase in atrial 
cycle length variability. 
Background. Conversion of tachyarrhythmias has been associ- 
ated with increased oscillations of cycle length. 
Methods. Electrograms and monophasic action potentials from 
the right atrium in 35 patients with spontaneous, ustained atrial 
flutter were recorded before, during and after intravenous ibuti- 
lide (0.005 to 0.025 mg/kg body weight, n = 25) or placebo (n = 
10). Atrial cycle length, cycle length variability (coefficient of 
variation), diastolic interval and diastolic interval variability were 
measured from 10 consecutive cycles at baseline and 3 rain before, 
1 min before, 30 s before and immediately before conversion. 
Similar measurements were made in patients who received ibuti- 
lide or placebo but did not convert. 
Results. Ibutilide converted atrial flutter in 14 of 25 patients 
25 _+ 16 min (mean -+ SD) after initiation of the infusion, whereas 
placebo converted no patients. Atrial cycle length was prolonged 
to the same extent in ibutilide converters and nonconverters (36 -+ 
19 vs. 38 -+ 21 ms, p = NS) and was not affected by placebo. 
Beat-to-beat variability in atrial cycle length (baseline 1.2 -+ 0.7 
vs. preconversion 7.3 -+ 4.9, p < 0.01) and diastolic interval 
(baseline 11 -+ 8 vs. preconversion 33 -+ 23, p < 0.05) increased 
significantly just before atrial flutter conversion and remained 
unchanged in ibutilide nonconverters and placebo group patients. 
Conclusions. Ibutilide prolongs atrial flutter cycle length, but 
conversion of atrial flutter by ibutilide is characterized by in- 
creased variability in atrial cycle length and diastolic interval. 
(JAm Coil Cardiol 1996;27:1083-9) 
Ibutilide, a new class III antiarrhythmic agent under clinical 
development, prolongs atrial and ventricular action potential 
duration (1) and refractoriness (2) and terminates atrial fibril- 
lation and flutter (3,4) and ventricular tachycardia (5). In- 
creased cycle length variability is associated with spontaneous 
and pharmacologically induced termination of supraventricu- 
lar (6-9) and ventricular tachycardia (10,11). Recent experi- 
mental studies in canine atrial flutter using a tricuspid ring 
preparation (12,13) or a sterile pericarditis model (6) demon- 
strated an association between spontaneous termination and 
beat-to-beat cycle length oscillation. In contrast, in the canine 
model of atrial flutter created by intercaval lesions of the right 
atrium, D-sotalol (14,15) and N-acetylprocainamide (16), two 
class III antiarrhythmic agents, terminated atrial flutter with 
(15) or without significant changes (14,16) in cycle length 
variability. The relation between atrial cycle length variability 
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and termination of atrial flutter in humans has not been 
reported previously. The present study sought to test the 
hypothesis that conversion of atrial flutter by ibutilide in 
humans is characterized by an increase in beat-to-beat atrial 
cycle length variability rather than by an abrupt ermination. 
Methods  
Patients. Thirty-five patients referred to our clectrophysi- 
ology laboratory for cardioversion of atrial flutter comprised 
the study group. Patients received ibutilide (n = 25) or placebo 
(n = 10) as participants in one of two multicenter, double- 
blinded, randomized, placebo-controlled trials in which our 
center was a participating site. All patients had spontaneous, 
sustained atrial flutter with a duration of at least 2 days. Eleven 
of 35 patients had a previous history of atrial flutter. No 
patients were receiving class I or III antiarrhythmic agents at 
the time of the study. The protocols were approved by the 
Committee on the Conduct of Human Research at the Medical 
College of Virginia and McGuire Veterans Affairs Medical 
Center, and all patients gave written informed consent. 
Study protocol. Patients were studied in the postabsorptive 
state and were sedated with intravenous midazolam as needed. 
Surface leads 1, aVF and V 1 as well as a bipolar electrogram 
(filter 25 to 500 Hz) and monophasic action potential (filter 
direct current to 250 Hz) obtained by a monophasic action 
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Figure 1. Surface l ad aVF, bipolar electro- 
gram (EGM) and monophasic a tion poten- 
tial (MAP) recorded from the high right 
atrium (HRA) in a patient at baseline and just 
before conversion ofatrial flutter at 35 rain 
after the beginning ofibutilide infusion. Num. 
hers above the electrographic tracing are 
atrial flutter cycle length, and those above and 
below of the monophasic a tion potential 
tracings are the diastolic interval and mono- 
phasic action potential t 90% of repolariza- 
tion, respectively. Mean cycle length for 10 
consecutive cycles was 257 ms at baseline and 
259 ms just before conversion. The beat-to- 
beat variability in cycle length and diastolic 
interval were 1 and 2.4 at baseline and 14 and 
64 just before conversion, respectively. 
potential electrode catheter (EPT) from the high right atrium 
or the right atrial appendage were recorded (Arrhythmia 
Research Technology or Honeywell, Inc.). Patients given ibuti- 
lide were randomized to receive one of several dosing regi- 
mens as determined by the multicenter single dose or repeat 
dose ibutilide study in which they were participants. Patients 
were enrolled in the ibutilide dose-response tudy before the 
repeat dose study. Six patients participating in the ibutilide 
single dose study were given an intravenous infusion of ibuti- 
lide (0.005, 0.01, 0.015 or 0.025 mg/kg body weight) over a 
10-rain period. Twenty-nine patients participating in the repeat 
dose study were randomized to receive either two 10-min 
intravenous infusions of ibutilide or placebo. In the repeat 
dose study, patients were given a l-rag (0.01 mg/kg) ibutilide 
infusion or placebo over 10 min and were observed for an 
additional 10 rain after completion of the infusion. If atrial 
flutter was not terminated within 10 rain of the first infusion, a 
second dose of 1 mg (0.01 mg/kg) or 0.5 mg (0.005 mg/kg) of 
ibutilide or placebo (same as the first infusion) was given over 
a second 10-rain period. After completion of the infusion of 
ibutilide, the surface electrocardiogram (ECG), right atrial 
electrogram and MAP recordings and blood pressure were 
monitored continuously for atrial flutter termination for 1 h. 
Data analysis. Because spontaneous beat-to-beat cycle 
length oscillation began 6 or 7 beats before conversion in a 
canine model of atrial flutter (6), the mean atrial flutter cycle 
length and beat-to-beat cycle length variability, the monopha- 
sic action potential duration measured at 90% repolarization, 
the diastolic interval, calculated as the difference between cycle 
length and monophasic action potential duration, and the 
beat-to-beat diastolic interval variability were calculated from 
10 consecutive cycles (Fig. 1). The coefficient of variation 
(SD/mean × 100%) was used as an index of beat-to-beat 
variability in atrial cycle length and diastolic interval. Measure- 
ments of atrial cycle length and monophasic action potential 
duration were made manually at a paper speed of 100 mm/s to 
an estimated precision of 3 ms and were made blinded to 
whether the patient received ibutilide or placebo. In patients 
receiving ibutilide who converted to sinus rhythm, the mean 
atrial flutter cycle length and coefficient of variation were 
measured at standard intervals of baseline, 3min before, 1 min 
before, 30 s before, and the 10 cycles immediately before 
conversion to sinus rhythm. In patients receiving placebo or 
ibutilide who did not convert, the same measurements were 
made at baseline, 15 rain after, 35 rain after and 70 rain after 
the beginning of the infusion. Monophasic action potential 
duration, diastolic interval and diastolic interval coefficient of 
variation were measured at baseline and either immediately 
before termination of atrial flutter or at the end of the 
observation period. 
Statistics, The differences in variables between two groups 
were determined by a paired or nonpaired t test. The differ- 
ences in variables among roups and repeated measurements 
within groups were determined by analysis of variance followed 
by Bonferroni multiple comparison test. Probability levels of 
less than 0.05 were considered statistically significant (paired 
or unpaired t test). Probability levels for the Bonferroni test 
were adjusted epending on the number of comparisons. All 
data are presented as mean _+ standard eviation. 
Resu l ts  
Clinical characteristics of study patients. The clinical 
characteristics of study patients are shown in Table 1. There 
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Table 1. Clinical Characteristics of Study Patients 
lbutilide Ibutilide Placebo 
Converters Nonconverters Group 
(n = 14) (n = 11) (n = 10) 
Age (yr) 67 + 8 68 _+ 7 66 -+ 10 
Male/female (% male) 13/1 (93) 11/0 (100) 9/1 (90) 
Duration of AFL (days) l0 _+ 12 25 + 21 11 _+ 13 
Previous history of AFL 5 (36) 2 (18) 4 (40) 
Underlying heart disease 
Coronary artery disease 9 (64) 6 (55) 6 (60) 
Hypertension 5 (36) 6 (55) 4 (40) 
Congestive heart failure 4 (29) 2 (18) 4 (40) 
Valvular heart disease 2 (14) 0 (0) 1 (10) 
Heart transplantation 1 (7) 0 (0) 0 (0) 
Left atrial size (cm) 4.6 : 0.7 4.2 m 0.8 4.3 -+ 0.5 
Left ventricular EF (%) 33 -+ 15 45 _+ 18 39 _+ 14 
Unless otherwise indicated, data presented are mean value (_+SD) or 
number (%) of patients. AFL - atrial flutter; EF - ejection fraction. 
were no significant differences among the three groups in any 
clinical variable. In particular, no clinical variable consistently 
predicted conversion of atrial flutter by ibutiiide. 
Conversion of atrial flutter. Atrial flutter was converted to 
sinus rhythm in 14 of 25 patients receiving ibutilide. The 
conversion time ranged from 9 to 64 min after the beginning of 
the infusion, with a mean conversion time of 25 _+ 16 rain 
(mean _+ SD). Of these 14 patients, 6 patients received two 
l-rag doses, 1 patient received 1mg plus 0.5 mg, and 7 patients 
received 1 mg alone. Data from these 14 patients were 
analyzed in group 1 (ibutilide converters). Atrial flutter was 
not terminated in six patients who received a single dose of 
ibutilide (0.005 mg/kg, n = 1; 0.01 mg/kg, n = 1; 0.015 mg/kg, 
n = 1; 0.025 mg/kg, n = 3) and in five patients who received 
repeat doses of ibutilide (1 mg plus 0.5 rag, n = 3; 1 mg plus 
1 rag, n = 2). These 11 patients were grouped together for 
statistical analysis (ibutilide nonconverters, group 2). There 
was no difference in ibutilide dose between groups 1 and 2 (p = 
NS). None of the patients receiving placebo (group 3, n = 10) 
experienced conversion of atrial flutter. 
Atrial flutter cycle length and cycle length variability. All 
patients had type I atrial flutter as defined by an atrial cycle 
length greater than 176 ms (340 beats/rain) (17). There were 
no statistical differences in baseline atrial flutter cycle length 
and in baseline beat-to-beat cycle length variability (all p > 
0.05) among the three groups (Table 2). Ibutilide infusion had 
no significant effect on blood pressure. Ibutilide significantly 
increased the atrial flutter cycle length (p < 0.01) to a similar 
extent in groups 1 (converters) and 2 (nonconverters) by36 _+ 
19 ms and 38 + 21 ms, respectively (p = NS) (Fig. 2 and 3). In 
ibutilide converters (group 1), there was a significant increase 
in atrial cycle length variability, which occurred only in the 10 
cycles just before conversion (coefficient of variation 7.3 _+ 4.9 
versus 1.2 _+ 0.7 at baseline, p < 0.01) (Fig. 2). In ibutilide 
nonconverters (group 2), cycle length variability did not change 
significantly throughout the observation period as compared to 
the baseline, despite persistent prolongation of cycle length 
Table 2. Baseline Atrial Flutter Cycle Length and Cycle Length 
Variability (mean _+ SD) 
Baseline Baseline 
Cycle Length Cycle Length 
(ms) Variability 
Ibutilide converters (n = 14) 240 _+ 30 
Ibutilide nonconverters (n = 11) 254 _+ 30 
Placebo group (n = 10) 227 _+ 39 
1.2 + 0.7 
1.8 -+ 1.5 
1.8 -+ 1.0 
following ibutilide infusion (Fig. 3). Neither cycle length nor 
cycle length variability Changed significantly in the placebo 
group (group 3) (Fig. 4). 
Oscillatory pattern. Examination of the beat-to-beat cycle 
length variation just before conversion in group 1 (ibutilide 
converters) did not reveal a specific oscillatory pattern (Fig. 5). 
This became apparent by examining the last two cycles prior to 
termination. Termination of the atrial flutter was preceded by 
a long-short pattern in five patients, a short-long pattern in six 
patients and no apparent changes in cycle length on the last 
two intervals in three patients. 
Diastolic interval variability. Stable monophasic action 
potential recordings were obtained at baseline and just before 
conversion in seven patients in group 1 (ibutilide converters), 
six patients in group 2 (ibutilide nonconverters) and five 
patients in group 3 (placebo). The diastolic intervals tended to 
be shortened ingroup 1 (ibutilide converters -14 _+ 17 ms, p < 
0.1) and did not change in group 2 (ibutilide nonconverters 
0 _+ 7 ms) or in group 3 (placebo 9 + 10 ms, p > 0.1). Similar 
to cycle length variability, diastolic interval variability in- 
creased only in ibutilide converters (group 1, from 11 _+ 8 at 
baseline to 33 + 23 at conversion, p < 0.05) (Fig. 6). Again 
there was no consistent oscillatory pattern of diastolic interval 
in the converters. By linear regression analysis, a significant 
correlation between diastolic interval and the subsequent cycle 
length or the subsequent monophasic action potential was not 
demonstrated. 
Discuss ion  
The present study demonstrates in patients with spontane- 
ous, sustained atrial flutter that conversion of atrial flutter by 
ibutilide is characterized by a marked increase in beat-to-beat 
variability in atrial flutter cycle length and diastolic interval 
that occurs just before conversion rather than by an abrupt 
termination. Prolongation of atrial flutter cycle length does not 
predict the success of conversion. This is supported by the 
findings in group 1, ibutilide converters, inwhich prolongation 
of atrial flutter cycle length was not related temporally to the 
increase in cycle length variability or to the termination of 
atrial flutter. Furthermore, in group 2, ibutilide nonconverters, 
there was sustained prolongation of atrial flutter cycle length 
without a significant change in cycle length variability or 
conversion of atrial flutter. Finally, there were no significant, 
spontaneous changes in cycle length variability in the placebo 
group. Thus, a significant increase in atrial cycle length vari- 
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Figure 2. Atrial flutter cycle length and beat- 
to-beat cycle length variability in converters 
(group 1, n = 14) at baseline (B) and 3 rain 
before, 1 rain before, 30 s before and just 
before conversion in response to ibutilide 
infusion. *p < 0.01 versus baseline. 
ability is associated with imminent conversion of atrial flutter 
in humans. 
Physiologic basis of cycle length variability. A premature 
stimulus or an abrupt change in heart rate may provoke 
oscillation in conduction velocity and refractoriness atcertain 
sites in a reentrant circuit (12,13,15,18,19). The degree of 
oscillation at a given site of the reentrant circuit forms the basis 
of beat-to-beat cycle length variability and may be important to 
maintain the stability of a reentrant tachycardia. A reentrant 
tachycardia becomes table and sustains itself if the oscillation 
dampens and will terminate if the oscillation becomes progres- 
sively greater. This concept has been supported by many 
observations that an increase in cycle length variability is 
associated with termination of supraventricular (6-9) and 
ventricular tachyeardia (10,11). The present study adds to 
these observations by demonstrating a similar finding in human 
atrial flutter terminated by ibutilide, a new class III antiar- 
rhythmic agent. 
The mechanism of cycle length oscillation and termination 
of atrial flutter has been studied extensively in animal models. 
In the canine atrial tricuspid ring preparation (12,13), conduc- 
tion velocity and refractoriness vary from site to site in the 
reentrant circuit and depend on the duration of the preceding 
diastolic interval, resulting in a complex oscillation of cycle 
length. In this model, a critical event for termination of the 
arrhythmia isan exceptionally long diastolic interval preceding 
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Figure 3. Atrial flutter cycle length and beat- 
to-beat cycle length variability after ibutilide 
infusion in nonconverters (group 2, n = 11). 
Data shown were taken at baseline (B) and 15, 
35 and 70 min after the beginning of infusion. 
*p < 0.0l versus baseline. 
JACC gol .  27, No. 5 GUO ET  AL. 1087 
April  1996:1083-9 ATRIAL  FLUTTER CYCLE LENGTH VARIAB IL ITY  
Figure 4. Atrial flutter cycle length and beat-to- 
beat cycle length variability inthe placebo group 
(group 3, n = 10). Data shown were taken at 
baseline (B) and 15, 35 and 70 min after the 
beginning of infusion. 
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the next-to-last cycle that accelerates local conduction and 
prolongs action potential duration and refractoriness at the 
site. In the canine sterile pericarditis model of atrial flutter, 
spontaneous termination of atrial flutter is likewise preceded 
by a consistent oscillatory pattern occurring over the last two 
beats: a long cycle followed by a much shorter cycle (6). The 
absence of a specific oscillatory pattern (i.e., long-short inter- 
vals) of cycle length or diastolic interval just before termination 
in the present study was most likely secondary to the recording 
site not being in the reentrant circuit or in a critical portion of 
the circuit. Mapping studies in human type I atrial flutter 
suggest a reentrant pathway with a critical area of slow 
conduction i  the inferior right atrium near the coronary sinus 
and inferior vena cava (20). In animal studies, spontaneous 
termination of atrial flutter or conversion with rapid pacing or 
antiarrhythmic drugs results from block of the impulse in the 
area of slow conduction in the circuit (6,21-23). During 
spontaneous termination of atrial flutter in experimental ni- 
mal models, the pattern of cycle length oscillations observed at 
the site of block may not be seen in other areas of the circuit 
(6,12). Thus, it may be difficult to prove or exclude a role for 
oscillations in terminating clinical arrhythmias, especially when 
recording outside the circuit. Inconsistent patterns of cycle 
length variability recorded in the surface electrocardiogram 
during spontaneous termination of ventricular tachycardia in 
patients with coronary artery disease have been reported 
previously (10,11). Oscillations in refractoriness with a nearly 
constant beat o-beat cycle length can also result in termination 
of tachyarrhythmias n experimental models (12). Local varia- 
tion in the conduction time may be exactly compensated by 
changes elsewhere in the circuit so that cycle length may be 
nearly constant if not recorded from within the circuit. These 
observations may explain the findings in the present study of 
different patterns of cycle length variability and the apparent 
absence of an increase in variability in some patients whose 
atrial flutter was terminated by ibutilide. 
Although it was not proven by the present study, it is 
tempting to speculate on a potential mechanism for the 
ibutilide-induced increase in variability in cycle length and 
diastolic interval that occurs just before termination of atrial 
flutter. Ibutilide may induce transient beat-to-beat changes in 
action potential duration, refractoriness and diastolic interval 
and produce unstable oscillations in the reentrant circuit. 
These alterations would tend to close the excitable gap and 
change the reentrant circuit from one that has a fully excitable 
gap (24) into one in which the impulse propagates through 
partially refractory tissue. Of interest, the increase in diastolic 
interval variability was greater than atrial cycle length variabil- 
ity. This indicates that beat-to-beat monophasic action poten- 
tial duration variation exceeded beat-to-beat cycle length 
variation. Thus, changes in action potential duration may 
produce changes in refractory period that contribute to and 
may be the primary driving force producing oscillations of cycle 
length and termination of atrial flutter. 
Other potentially important mechanisms of cycle length 
oscillations have been suggested by other animal studies. 
However, the present study's data cannot specifically address 
these alternatives. In the canine model of atrial flutter created 
by an anatomic barrier (14,15), oscillation of cycle length, in 
addition to resulting from changes in conduction velocity, may 
also occur as a result of a change in the pathway length or 
disturbance of the pathway by a competing focus. D-Sotalo1 
administration terminates atrial flutter in the anatomic barrier 
model by conduction block of the reentrant impulse within the 
fixed pathway or by interruption of the original circuit when 
there was a failure of a lateral boundary as evidenced by a 
premature xcitation at one site of the circus path preceding 
the wavefront block (14,15). 
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Figure 5. Atrial flutter cycle lengths during the last 10 cycles just 
before termination (T) of atrial flutter by ibutilide in 14 converters 
(group 1). No specific oscillatory pattern of cycle length is seen just 
before termination. 
Comparison with other antiarrhythmic agents. Termina- 
tion of atrial flutter in canine models by class I antiarrhythmic 
agents uch as procainamide (16,23), moricizine (22), disopyr- 
amide (14,25), propafenone (14,25), flecainide (14,25) or SC- 
40230 (14) occurs by increasing cycle length and preferentially 
suppressing conduction in the area of slow conduction rather 
than by prolongation of refractoriness. The class III antiar- 
rhythmic agents E-4301 (25) and D-sotalol (14) terminate 
canine atrial flutter by decreasing the excitable gap through a 
greater prolongation of refractoriness and a lesser slowing of 
conduction. In another study from our laboratory, the en- 
hanced conversion efficacy of ibutilide in patients with atrial 
flutter compared to procainamide was likewise caused by a 
relatively greater prolongation of monophasic action potential 
duration compared to cycle length (3). In contrast, N- 
acetylprocainamide, another class III antiarrhythmic agent, 
terminates canine atrial flutter without decreasing the excit- 
able gap (16). Not all canine studies of pharmacologic termi- 
nation of atrial flutter have demonstrated consistent patterns 
of atrial cycle length variability prior to termination. N- 
Acetylprocainamide (16) and E-4031 (25) terminate canine 
atrial flutter with no or minimal cycle length variability, and 
termination of atrial flutter with D-sotalol may be associated 
with (15) or without (14) changes in cycle length variability. 
These studies emphasize that various animal models of atrial 
flutter, and humans may respond ifferently to antiarrhythmic 
agents (26). 
Study limitations. As already discussed, a major limitation 
of the present study is that the recordings of atrial electro- 
grams and monophasic action potentials were undoubtedly not 
made from within the atrial flutter reentrant circuit and thus 
may not reflect conduction velocity, refractoriness or cycle 
length in the critical area of slow conduction. No attempt was 
made to define the reentrant circuit and obtain recordings 
directly from it. The instability and loss of monophasic action 
potential recordings in some patients limited the power of 
statistics and precluded the study of time course changes in 
diastolic interval variability. Because not every beat of atrial 
flutter cycle length was measured, transient oscillations of cycle 
length that were not associated with atrial flutter termination 
may have been missed. It seems unlikely, however, that the 
conclusions of the study would have been altered even if every 
beat of atrial flutter had been measured because both the 
placebo and ibutilide nonconverter groups demonstrated no 
significant change and a trend to a decrease in cycle length 
variability. Another limitation of this study is that various doses 
of ibutilide were used based on the randomization scheme of 
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F igure  6. Diastolic interval variability (coefficient of variation) at 
baseline (B), just before conversion (C) in ibutilide converters (group 
1, n = 7) and 70 rain after (A) ibutilide or placebo infusion in ibutilide 
nonconverters (group 2, n = 6) and in placebo group patients (group 
3, n = 5). *p < 0.05 versus baseline, 
the multicenter trial in which the patients were enrolled. 
Finally, the present study cannot comment on whether cycle 
length variability at termination of atrial flutter is specific to 
ibutilide's mechanism of action or might be seen with other 
drugs or modes of termination in humans. 
Conclusions. Ibutilide prolongs atrial flutter cycle length, 
but conversion of atrial flutter is characterized by a sudden, 
transient increase in beat-to-beat variability of atrial cycle 
length and diastolic interval that occurs just before conversion. 
These results provide potential insights into the mechanism of 
conversion of atrial flutter in humans by ibutilide. 
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